Back to Agenda
Welcome, Opening Remarks, and Session 1: International Updates on RWE in Regulatory Decision Making
Session Chair(s)
Nancy A Dreyer, PhD, MPH, FISPE
Founder
Dreyer Strategies LLC, United States
Debra Schaumberg, DrSc, MPH
Vice President and Global Head, Startegic Development Consulting Chair
Evidera | PPD, United States
The advent of the global pandemic of COVID-19, and the resulting imperative for rapid evidence generation, has catapulted conversations around the role of RWE in regulatory decision-making, resulting in both answers and more questions about when RWE is fit-for-use; including retractions of RWE-based manuscripts from major medical journals. This session will bring together regulatory leaders from the United States, Europe, and Japan to discuss recent lessons learned about RWE and its application to the regulatory context, and the frameworks being developed to interrogate such evidence and inform when it can be trusted.
Learning Objective : - Describe the current regulatory perspectives on benefits and challenges of using RWE in regulatory decisions
- Identify challenges to use of RWE in different contexts (e.g. pre- and post-approval), and key factors considered for discriminating between RWE that can and cannot be trusted
- Compare regulatory frameworks for consideration of RWE in regulatory decision-making in three major geographies of importance to the pharmaceutical community (US, EMA and Japan)
Speaker(s)
Welcome and Opening Remarks
Robin M. Weinick, PhD
DIA, United States
SVP/Managing Director Americas and Global Program Officer
Speaker
Amy Abernethy, MD, PhD
Alphabet’s Verily, United States
President of Clinical Studies Platforms
Speaker
Peter Richard Arlett, MD, FFPM, FRCP
European Medicines Agency, Netherlands
Head Data Analytics and Methods Task Force
Speaker
Yoshiaki Uyama, PhD, RPh
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Associate Executive Director
Have an account?